Established in 2019，Pure Bio Medical Jiangsu Ltd. was a fully-owned subsidiary of Nanjing Chia-Tai Tianqing Pharmaceutical Company. Ltd. (NJCTTQ), an innovative pharmaceutical enterprise integrating R&D, production, and sales under the Chia-Tai Pharmaceutical Group.

  The company is located in the Jiangbei New Area of Nanjing National-level Free Trade Zone, covering an area of 20 hectares with a total investment of approximately 1.87 billion yuan, and has been included in the "Major Economic and Social Development Projects of Nanjing City from 2020 to 2023". The main business includes R&D, production, and sales of APIs, traditional Chinese medicine extracts and preparations, and biologics, with core therapeutic areas covering cardiovascular, tumor, and perioperative.

  Pure Bio Medical follows the strategic positioning of "building platforms, high standards, and internationalization", benchmarking with leading pharmaceutical companies at home and abroad. It possesses hazardous reaction platforms such as hydrogenation, amination, sulfonation, oxidation, alkylation, and diazotization. And through the support of DCS, SIS, and five-in-one platform, it can achieve customized production of "sealing, pipelining, automation, and informatization". It has the capability to undertake CMO and CDMO businesses. Currently, there are 5 API workshops and 1 traditional Chinese medicine extraction workshop, with a total of 10 independent production lines, with an annual production capacity of up to 1,000 metric tons.